↓ Skip to main content

American College of Cardiology

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction Rationale and Design of the PARAGON-HF Trial

Overview of attention for article published in JACC: Heart Failure, June 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#15 of 1,595)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
40 news outlets
twitter
85 X users
facebook
5 Facebook pages

Citations

dimensions_citation
268 Dimensions

Readers on

mendeley
271 Mendeley
Title
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction Rationale and Design of the PARAGON-HF Trial
Published in
JACC: Heart Failure, June 2017
DOI 10.1016/j.jchf.2017.04.013
Pubmed ID
Authors

Scott D. Solomon, Adel R. Rizkala, Jianjian Gong, Wenyan Wang, Inder S. Anand, Junbo Ge, Carolyn S.P. Lam, Aldo P. Maggioni, Felipe Martinez, Milton Packer, Marc A. Pfeffer, Burkert Pieske, Margaret M. Redfield, Jean L. Rouleau, Dirk J. Van Veldhuisen, Faiez Zannad, Michael R. Zile, Akshay S. Desai, Victor C. Shi, Martin P. Lefkowitz, John J.V. McMurray

Abstract

The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy and safety of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan compared with valsartan in patients with chronic heart failure and preserved ejection fraction (HFpEF). HFpEF is highly prevalent, associated with substantial morbidity and mortality, and in need of effective therapies that improve outcomes. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan, which has been shown to benefit patients with heart failure (HF) and reduced ejection fraction, demonstrated favorable physiologic effects in a phase II HFpEF trial. The PARAGON-HF trial is a randomized, double-blind, parallel group, active-controlled, event-driven trial comparing the long-term efficacy and safety of valsartan and sacubitril/valsartan in patients with chronic HFpEF (left ventricular ejection fraction ≥45%), New York Heart Association functional class II to IV symptoms, elevated natriuretic peptides, and evidence of structural heart disease. Before randomization, all patients entered sequential single-blind run-in periods to ensure tolerability of both drugs at half the target doses (i.e., valsartan titrated to 80 mg bid followed by sacubitril/valsartan 49/51 mg [100 mg] bid). The primary outcome is the composite of cardiovascular death and total (first and recurrent) HF hospitalizations. PARAGON-HF will determine whether sacubitril/valsartan is superior to angiotensin receptor blockade alone in patients with chronic symptomatic HFpEF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).

X Demographics

X Demographics

The data shown below were collected from the profiles of 85 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 271 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Unknown 270 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 44 16%
Student > Postgraduate 25 9%
Student > Bachelor 24 9%
Student > Doctoral Student 23 8%
Other 23 8%
Other 61 23%
Unknown 71 26%
Readers by discipline Count As %
Medicine and Dentistry 138 51%
Biochemistry, Genetics and Molecular Biology 10 4%
Pharmacology, Toxicology and Pharmaceutical Science 9 3%
Engineering 6 2%
Nursing and Health Professions 5 2%
Other 21 8%
Unknown 82 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 328. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2021.
All research outputs
#102,066
of 25,461,852 outputs
Outputs from JACC: Heart Failure
#15
of 1,595 outputs
Outputs of similar age
#2,268
of 328,569 outputs
Outputs of similar age from JACC: Heart Failure
#3
of 28 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,595 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,569 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.